Pralsetinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 296 publications

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.

Journal: Frontiers in oncology

Published: July 16, 2026

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Journal: Thyroid : official journal of the American Thyroid Association

Published: June 24, 2026

Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a "chemical adaptation" strategy.

Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a "chemical adaptation" strategy.

Journal: Bioorganic chemistry

Published: June 16, 2026

Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)

Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: May 20, 2026

Molecular clusters and precision medicine in pheochromocytomas and paragangliomas.

Molecular clusters and precision medicine in pheochromocytomas and paragangliomas.

Journal: Endocrine-related cancer

Published: May 19, 2026

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

Journal: Pharmacological research

Published: May 05, 2026

Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.

Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.

Journal: Investigational new drugs

Published: May 05, 2026

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 26, 2026

Induction therapy of pralsetinib followed by conversion surgery for unresectable locally advanced non-small cell lung cancer with the rearranged during transfection (RET) fusion gene mutation: protocol for a single-arm phase II prospective trial (the SALVAGE-P trial).

Induction therapy of pralsetinib followed by conversion surgery for unresectable locally advanced non-small cell lung cancer with the rearranged during transfection (RET) fusion gene mutation: protocol for a single-arm phase II prospective trial (the SALVAGE-P trial).

Journal: Journal of thoracic disease

Published: March 16, 2026

GDNF-RET signaling drives pulmonary neuroendocrine cell hyperplasia and allergic airway inflammation.

GDNF-RET signaling drives pulmonary neuroendocrine cell hyperplasia and allergic airway inflammation.

Journal: FEBS letters

Published: March 09, 2026

Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report.

Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report.

Journal: Lung Cancer (Auckland, N.Z.)

Published: February 28, 2026

Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.

Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.

Journal: Tumori

Published: February 06, 2026

Showing 1-12 of 296

Last Updated: 09/26/2026